New drug combo aims to shrink hard-to-treat tumors
NCT ID NCT06422520
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells. It is given alone or with another drug (tislelizumab) that helps the immune system attack cancer. The study includes about 120 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215-5418, United States
-
Florida Cancer Specialist Research Institute Lake Nona
Orlando, Florida, 32827-7400, United States
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Next Oncology
San Antonio, Texas, 78229-6028, United States
-
One Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
St Vincents Hospital Melbourne
Fitzroy, Victoria, VIC 3065, Australia
-
The Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Westmead Hospital
Westmead, New South Wales, NSW 2145, Australia
Conditions
Explore the condition pages connected to this study.